Loss of Neutralizing Activity of Tixagevimab/Cilgavimab (Evusheld™) Against Omicron BN.1, a Dominant Circulating Strain Following BA.5 During the Seventh Domestic Outbreak in Korea in Early 2023-Reference-Cited by-同舟云学术

Loss of Neutralizing Activity of Tixagevimab/Cilgavimab (Evusheld™) Against Omicron BN.1, a Dominant Circulating Strain Following BA.5 During the Seventh Domestic Outbreak in Korea in Early 2023

Published:2023 Issue:27 Volume:38 Page:
ISSN:1011-8934
Container-title:Journal of Korean Medical Science
language:en
Short-container-title:J Korean Med Sci

Author:

Yang Jinyoung¹^ORCID,Hyeon Seokhwan²^ORCID,Baek Jin Yang¹³^ORCID,Kang Min Seo¹^ORCID,Lee Keon Young¹^ORCID,Lee Young Ho¹^ORCID,Huh Kyungmin¹^ORCID,Cho Sun Young¹^ORCID,Kang Cheol-In¹^ORCID,Chung Doo Ryeon¹^ORCID,Peck Kyong Ran¹^ORCID,Won Gunho²^ORCID,Lee Hye Won²^ORCID,Kim Kwangwook²^ORCID,Hwang Insu²^ORCID,Lee So Yeon²^ORCID,Kim Byung Chul²^ORCID,Lee Yoo-kyoung²^ORCID,Ko Jae-Hoon¹^ORCID

Affiliation:

1. Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

2. Division of Vaccine Development Coordination, Center for Vaccine Research, National Institute of Infectious Diseases, National Institute of Health, Korea Disease Control and Prevention Agency, Cheongju, Korea.

3. Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, Korea.

Funder

Korea Disease Control and Prevention Agency

Samsung Medical Center

Publisher

XMLink

Subject

General Medicine

Link

https://jkms.org/pdf/10.3346/jkms.2023.38.e205

Reference17 articles.

1. Neutralizing activity against Omicron BA.5 after tixagevimab/cilgavimab administration comparable to those after Omicron BA.1/BA.2 breakthrough infections

2. World Health Organization. Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern. Updated 2021. Accessed on April 10, 2023. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern

3. Importation and Transmission of SARS-CoV-2 B.1.1.529 (Omicron) Variant of Concern in Korea, November 2021

4. COVID ‘variant soup’ is making winter surges hard to predict. Updated 2022. Accessed on April 10, 2023. https://www.nature.com/articles/d41586-022-03445-6

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation of severe acute respiratory syndrome coronavirus 2 infection status in solid organ transplant recipients treated with tixagevimab/cilgavimab;Journal of Infection and Chemotherapy;2024-05

2. Evolution of neutralizing antibodies through vaccination and breakthrough infections in the era of COVID‐19 endemicity;Journal of Medical Virology;2023-12

3. Clinical utility of quantitative immunoassays and surrogate virus neutralization tests for predicting neutralizing activity against the SARS‐CoV‐2 Omicron BA.1 and BA.5 variants;Journal of Medical Virology;2023-12